Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD.

Lee G, You HJ, Bajaj JS, Joo SK, Yu J, Park S, Kang H, Park JH, Kim JH, Lee DH, Lee S, Kim W, Ko G. · 2020

Read Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD. by Lee G, You HJ, Bajaj JS, Joo SK, Yu J, Park S, Kang H, Park JH, Kim JH, Lee DH, Lee S, Kim W, Ko G. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7536225.txt.

Introduction

Lee and co-authors link gut microbes to liver scarring in non-obese fatty liver disease. Fatty liver is often tied to obesity. It also occurs in people who are not obese.

The team profiled 171 Asian patients with biopsy-proven disease. They also studied 31 controls without the disease. Sequencing used 16S rRNA from stool samples. A Western cohort served for outside validation. Microbe diversity shifted with fibrosis severity in non-obese patients. Two families, Ruminococcaceae and Veillonellaceae, stood out. Stool bile acids and propionate were higher in severe cases. Mouse tests then checked four species for liver effects.

Catalog record

CREATORLee G, You HJ, Bajaj JS, Joo SK, Yu J, Park S, Kang H, Park JH, Kim JH, Lee DH, Lee S, Kim W, Ko G.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE64 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7536225

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD By Giljae Lee, Hyun Ju You, Jasmohan S Bajaj, Sae Kyung Joo, Junsun Yu, Seoyeon Park, Hyena Kang, Jeong Hwan Park, Jung Ho Kim, Dong Hyeon Lee, Seonhwa Lee, Won Kim Published in: Nature Communications DOI: 10.1038/s41467-020-18754-5 ABSTRACT Abstract Nonalcoholic fatty liver disease (NAFLD) is associated with obesity but also found in non-obese individuals. Gut microbiome profiles of 171 Asians with biopsy-proven NAFLD and 31 non-NAFLD controls are analyzed using 16S rRNA sequencing; an independent Western cohort is used for external validation. Subjects are classified into three subgroups according to histological spectra of NAFLD or fibrosis severity. Significant alterations in microbiome diversity are observed according to fibrosis severity in non-obese, but not obese, subjects. Ruminococcaceae and Veillonellaceae are the main microbiota associated with fibrosis severity in non-obese subjects. Furthermore, stool bile acids and propionate are elevated, especially in non-obese subjects with significant fibrosis. Fibrosis-related Ruminococcaceae and Veillonellaceae species undergo metagenome sequencing, and four representative species are administered in three mouse NAFLD models to evaluate their effects on liver damage. This study provides the evidence for the role of the microbiome in the liver fibrosis pathogenesis, especially in non-obese subjects. Subject terms: Microbiome, Diagnostic markers, Liver fibrosis INTRODUCTION Nonalcoholic fatty liver disease (NAFLD) is characterized by hepatic manifestations of metabolic disorders, ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), an aggressive histological form, ultimately leading to advanced fibrosis and cirrhosis. The global prevalence of NAFLD is estimated to be 24–30% in most epidemiological studies and is increasing in parallel with obesity and metabolic syndrome1. Although NAFLD is usually linked to obesity, NAFLD also occurs in non-obese subjects presenting with pathological severities similar to those observed in obese NAFLD patients2,3. In both the West and the East, 3–30% of non-obese populations are consistently reported to have NAFLD, without considering different body mass index (BMI) cut-offs for defining obesity (≥25 in Asians vs. ≥30 in other ethnicities)4. Although visceral fat, dietary composition, and genetic factors can be associated with non-obese NAFLD5, additional studies considering other environmental factors are required to elucidate the pathogenesis of non-obese NAFLD. Increased interest has recently focused on identifying and understanding the specific role of the intestinal microbiota in various metabolic diseases. Gut dysbiosis has been associated with a decrease in beneficial short-chain fatty acid (SCFA)-producing bacteria, changes in the composition of bile acids6, activation of immune responses against lipopolysaccharide (LPS)7, increased ethanol production by overgrowth of ethanol-producing bacteria8,9, and conversion of phosphatidylcholine to choline and trimethylamine10. Changes in the gut microbiota, which affect the gut-liver axis, are also associated with the progression of chronic liver disease and advanced fibrosis, such as NAFLD and cirrhosis11–15. However, the microbial taxa associated with disease severity and fibrosis stage are not consistent with those reported in previous NAFLD studies. This inconsistency could be due to the effects of regional differences16. However, differential underlying BMI status might also account for these inconsistent results. Here, the aims of this study are to determine whether the histological severity of NAFLD is associated with stool microbial changes in a well-characterized, biopsy-proven Asian NAFLD cohort and to explore microbial markers for the diagnosis of non-obese NAFLD. The 16S rRNA gene amplicon sequencing with 202 subjects stratified by obese status shows specific and distinct changes in the gut microbial community according to fibrosis severity, especially in non-obese subjects. After adjustments for age, sex, BMI, diabetes mellitus, and cirrhosis using multivariate association with linear models (MaAsLin), Ruminococcaceae and Veillonellaceae are the main microbial taxa associated with significant fibrosis in non-obese subjects. Moreover, stool primary bile acids and propionate levels are significantly elevated in non-obese subjects with worsening fibrosis severity. In bacterial taxa-metabolites networks according to fibrosis severity, strong inverse interactions between Veillonellaceae and Ruminococcaceae are noticeable and observed only in non-obese NAFLD subjects, implying the potential of the microbiome-based marker to diagnose fibrosis in non-obese NAFLD. The microbiome–metabolite combination suggested in this study significantly enhances the diagnostic power with an improved AUC of 0.939 (0.584 in all subjects; 0.520 in obese subjects), which is higher than that of fibrosis 4 index in non-obese subjects. We further conduct metagenomic shotgun sequencing of stool samples collected from 38 non-obese subjects, and species of Megamonas and Ruminococcus are identified as representative fibrosis-related taxa consisting of Veillonellaceae and Ruminococcaceae. The metagenome analysis also reveals the relationship between significantly downregulated microbial genes related to primary/secondary bile acid metabolism and increasing amounts of total conjugated bile acids and unconjugated primary bile acids in non-obese subjects with significant fibrosis. The protective or worsening effect of four strains of bacteria belonging to Ruminococcaceae and Veillonellaceae on liver damage is investigated using three different mouse NAFLD models. Ruminococcus faecis shows an alleviating effect on fibrosis including significantly regressed histological severity and decreased expression of fibrogenic genes (Col1a1, Timp1, and a-SMA). Taken together, the intestinal bacteria and related metabolites in the pathogenesis of non-obese NAFLD have the potential to be utilized as a fibrosis marker, as well as a therapeutic target. RESULTS Baseline characteristics of human subjects This study included 171 subjects with biopsy-proven NAFLD (NAFL, n = 88; NASH, n = 83) and 31 no-NAFLD controls. All of the study subjects were classified into two groups (non-obese, BMI < 25; obese, BMI ≥ 25), and each group was divided into three subgroups according to the histological spectra of NAFLD or fibrosis severity. Supplementary Tables 1 and 2 present the detailed characteristics of each group, including clinical, metabolic, biochemical, and histological profiles. Subjects with NASH or significant fibrosis (F2–4) had higher levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and insulin resistance in both the obese and non-obese groups. Subjects with significant fibrosis had higher NAFLD activity scores and presented more severe liver histology in terms of the histological classification of NAFLD (Supplementary Table 3 and Supplementary Fig. 1). More detailed baseline characteristics in each fibrosis stage, including well-known NAFLD-associated genetic variants, such as PNPLA3, TM6SF2, MBOAT7-TMC4, and SREBF-2, are shown in Supplementary Table 4. Microbial community changes according to fibrosis severity are different in non-obese and obese NAFLD subjects We analyzed data from 16S rRNA gene amplicon sequencing and compared the microbial diversity according to the histological spectra of NAFLD or fibrosis severity (Fig. 1). Alpha diversity based on the Shannon metric was plotted, and beta diversity based on the Bray–Curtis distance was plotted for comparison. No significant alterations in diversity among groups stratified by the histological spectra of NAFLD or fibrosis severity were observed (Fig. 1a). We then classified the subjects into two groups according to BMI status. In the non-obese group, a significant decrease in microbial diversity between F1 and F0 (P = 0.0074) as well as between F2–4 and F0 (P = 0.0084) was observed (Fig. 1b). Moreover, apparent clustering between F0 and F2–4 was observed (P = 0.038). In the obese group, no significant differences in diversity were found among groups stratified by the histological spectra of NAFLD or fibrosis severity (Fig. 1c). These results indicate that fibrosis severity rather than necroinflammatory activity is more likely associated with the changes of gut microbiome and underlying BMI status may also be an important factor responsible for alterations of the gut microbiome.

Read the complete text